Core B (Biostatistics and Data Management Core): Project Summary/Abstract Core B which has supported the PPG for >25 years, consists of a Core Leader (Lavori), a Core Physician leader (Lowsky), two Biostatisticians (Narasimhan and Tamaresis), and a Clinical Research Coordinator (Elder) who (in addition to her PPG work), supervises six Clinical Research Assistants who are supported by Stanford University Medical Center and other grants which provide services as needed to support the PPG aims. The leader of Core B and the two biostatisticians have decades of experience in medical research and, in particular, clinical trial design and data management work (organization, planning, management, monitoring and analysis) in collaboration with medical investigators, including many years of collective experience working with the BMT investigators. The Core B physician leader, Dr. Lowsky, has extensive experience in the development, conduct, data collection and analysis, study completion and monitoring of single center and multi-center clinical trials. The Core supports the clinical and preclinical projects and Core C in the proposal by leveraging the depth of expertise in analytics at Stanford University to assist project investigators in all aspects of their studies. Core B meets weekly to review and plan work, often joined by other key PPG personnel. The Core staff meet on a monthly basis with all clinical research assistants, the program project PI and the other clinical investigators, to resolve difficulties and problems, for example, in data collection, data flow, definitions, forms design and protocol development. Frequent ad hoc meetings between investigators and Core B members are scheduled, as needed. Each of the 5 new projects in the program project (on the basis of past experience and preparation of plans for the coming years to be supported through this program) will use about the same fraction of Core B effort (15% each) and the remainder is split between Core C (25%). The Core has 5 specific aims: 1) provide biostatistics consultation to the PPG project investigators for animal studies and clinical trials, 2) develop analytics for the TCR sequencing and immune monitoring assays generated by the massively parallel sequencing technologies deployed by Core C, 3) maintain the integrity of the data generated by the projects, 4) analyze data for scientific reports and annual IND and DSMC submissions, and 5) maintain the extensive BMT database. Core B is committed to active and continued participation in the PPG to help ensure that project Aims are fulfilled in the most scientifically meaningful manner.

Public Health Relevance

Core B (Biostatistics and Data Management Core): Project Narrative Core B supports the clinical and pre-clinical projects and Core C in the proposal by leveraging the depth of expertise in analytics at Stanford University to assist project investigators in all aspects of their studies. Core B has been successfully carrying out this mission for >25 years, and has helped the PPG investigators shape the field of Hematopoietic Cell Transplantation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049605-30
Application #
10018828
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-05-01
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
30
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Xu, Lian; Hunter, Zachary R; Tsakmaklis, Nicholas et al. (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol 172:735-44
Hinds, David A; Barnholt, Kimberly E; Mesa, Ruben A et al. (2016) Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 128:1121-8

Showing the most recent 10 out of 307 publications